Tolerability and efficacy of multidose formulations of epoetin beta

Clinical Drug Investigation

Volumn 13, Issue 4, 1997, Pages 199-206

  Franke, Werner ^a   Scherhag, Rudi ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; BENZYL ALCOHOL; RECOMBINANT ERYTHROPOIETIN; SOLVENT;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LYOPHILISATE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; MYALGIA; NORMAL HUMAN; PAIN; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030980657     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713040-00004     Document Type: Article

References (12)

1. Dunn CJ, Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 1996; 51 (2): 299-318
2. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8
3. Recormon® Data Sheet 1996
4. Expert Report on the chemical, pharmaceutical and biological documentation for NeoRecormon 50 000 and 10 000 IU multidose vials and 10 000 and 20 000 IU cartridges. Boehringer Mannheim report no AZ 613, 1995
5. Samtleben W, Baldamus CA, Bommer J, et al. Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients. Nephrol 1989; 76: 193
6. Scigalla P, Wieczorek L, Bicker U. Treatment of renal anaemia with recombinant human erythropoietin: European experience. In: Garnick MB, editor. Erythropoietin in clinical applications. New York, M Dekker, 1990: 141
7. Eschbach JW. The future of rhEPO. Nephrol Dial Transplant 1995; 10 Suppl. 2: 96-109
8. Macdougall IC. How to get the best out of rhEPO. Nephrol Dial Transplant 1995; 10 Suppl. 2: 85-91
9. Adverse event reporting on epoetin beta. Boehringer Mannheim Documentation AZ 510
10. Shannon KM, Keith JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Paediatrics 1995; 95 (1): 1-9
11. American Academy of Pediatrics. Benzyl alcohol: toxic agent in neonatal use. Paediatrics 1983; 72: 356-7
12. Santiero ML. Benzyl alcohol toxicity in newborn infants. J Hosp Pharm 1989; 9: 17-9